Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study

PURPOSE Arsenic combined with all-trans retinoic acid (ATRA) is the standard of care for adult acute promyelocytic leukemia (APL). However, the safety and effectiveness of this treatment in pediatric patients with APL have not been reported on the basis of larger sample sizes. METHODS We conducted a multicenter trial at 38 hospitals in China. Patients with newly diagnosed APL were stratified into two risk groups according to baseline WBC count and FLT3-ITD mutation. ATRA plus arsenic trioxide or oral arsenic without chemotherapy were administered to the standard-risk group, whereas ATRA, arsenic trioxide, or oral arsenic plus reduced-dose anthracycline were administered to the high-risk group. Primary end points were event-free survival and overall survival at 2 years. RESULTS We enrolled 193 patients with APL. After a median follow-up of 28.9 months, the 2-year overall survival rate was 99% (95% CI, 97 to 100) in the standard-risk group and 95% (95% CI, 90 to 100) in the high-risk group (P = .088). The 2-year event-free survival was 97% (95% CI, 93 to 100) in the standard-risk group and 90% (95% CI, 83 to 96) in the high-risk group (P = .252). The plasma levels of arsenic were significantly elevated after treatment, with a stable effective level ranging from 42.9 to 63.2 ng/mL during treatment. In addition, plasma, urine, hair, and nail arsenic levels rapidly decreased to normal 6 months after the end of treatment. CONCLUSION Arsenic combined with ATRA is effective and safe in pediatric patients with APL, although long-term follow-up is still needed.

[1]  J. Xie,et al.  Long-term follow-up of children with acute promyelocytic leukemia treated with Beijing Children’s Hospital APL 2005 protocol (BCH-APL 2005) , 2019, Pediatric hematology and oncology.

[2]  F. Lo Coco,et al.  The Simpler the Better: Oral Arsenic for Acute Promyelocytic Leukemia. , 2019, Blood.

[3]  Albert A. Taylor,et al.  Design and analysis of a clinical trial using previous trials as historical control , 2019, Clinical trials.

[4]  E. Estey,et al.  Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. , 2019, Blood.

[5]  F. Appelbaum,et al.  Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  Ke Huang,et al.  Multicenter randomized trial of arsenic trioxide and Realgar‐Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG‐APL clinical study , 2018, American journal of hematology.

[7]  Xiao-jun Huang,et al.  Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. , 2018, The Lancet. Oncology.

[8]  Ya-Zhen Qin,et al.  Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia. , 2018, Blood.

[9]  J. Krosl,et al.  Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin , 2018, Leukemia.

[10]  [Chinese guidelines for diagnosis and treatment of acute promyelocytic leukemia (2018)]. , 2018, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.

[11]  S. Raimondi,et al.  Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Estey,et al.  Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. , 2017, Blood.

[13]  Jiong Hu,et al.  The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia. , 2016, Blood.

[14]  F. Lo‐Coco,et al.  Current management of newly diagnosed acute promyelocytic leukemia. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  R. Schlenk,et al.  Targeted Therapy Alone for Acute Promyelocytic Leukemia. , 2016, The New England journal of medicine.

[16]  F. Lo‐Coco,et al.  Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients , 2016, Annals of Hematology.

[17]  Hao Jiang,et al.  Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia. , 2015, Leukemia research.

[18]  R. Hills,et al.  Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. , 2015, The Lancet. Oncology.

[19]  L. Campbell,et al.  Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. , 2015, The Lancet. Haematology.

[20]  P. Adamson,et al.  Principles and Practice of Pediatric Oncology (7th ed.) , 2015 .

[21]  S. Minucci,et al.  Activation of a promyelocytic leukemia–tumor protein 53 axis underlies acute promyelocytic leukemia cure , 2014, Nature Medicine.

[22]  Bin Wang,et al.  Long‐term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single‐centre experience , 2013, European journal of haematology.

[23]  Saijuan Chen,et al.  Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Saijuan Chen,et al.  Targeting agents alone to cure acute promyelocytic leukemia. , 2013, The New England journal of medicine.

[25]  Paola Fazi,et al.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.

[26]  S. Meshinchi,et al.  Children's Oncology Group's 2013 blueprint for research: Acute myeloid leukemia , 2013, Pediatric blood & cancer.

[27]  F. Lo‐Coco,et al.  Modern approaches to treating acute promyelocytic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Larson,et al.  Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. , 2010, Blood.

[29]  E. Estey,et al.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Esteve,et al.  Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. , 2009, Blood.

[31]  Zhen-yi Wang,et al.  Acute promyelocytic leukemia: from highly fatal to highly curable. , 2008, Blood.

[32]  E. Estey,et al.  Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. , 2006, Blood.

[33]  J. Esteve,et al.  From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 23, 2013. For personal use , 2000 .